Alcon acquires Neurotech for $550M, adding rare eye disease drug

October 20, 2026 4:35 PM

Alcon (SIX/NYSE: ALC) has acquired Neurotech Pharmaceuticals, Inc. for $550 million, gaining ownership of ENCELTO, the first FDA-approved treatment for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found